ASCO: Gilead and Arcus’s Cancer Immunotherapy Combo Faces Scrutiny Over Lower Survival Rates

Gilead Sciences and Arcus Biosciences face scrutiny as Phase II study results for their cancer immunotherapy combo reveal lower progression-free survival rates.